Month: March 2012

CARACAS (Reuters) – Venezuelan President Hugo Chavez returned Thursday morning to Caracas after receiving in Cuba the first cycle of radiation therapy to combat cancer afflicting, which will obligate you to maintain a virtual presence in the Government and to lower the pace in his career for re-election in October. An animated and smiling Chavez appeared live on the State channel VTV from one of the salons of the Miraflores Palace, headquarters of the Venezuelan Government, accompanied by several Ministers, with which he joked and sang up. “Is a hard battle (…) am well and will continue well”, commented Chavez on his health. “I have resisted very well treating, thank God.” “Still recovering me from my post operative,” added. Chávez in Havana’s stay coincided with the official Pope Benedict XVI’s visit to the island, but the President said that he would not seek a meeting with the Pontiff for not “interfere” with matters of State between the Vatican and Cuba. Socialist leader began Saturday in Havana, which in its first phase required five days consecutive application and treatment marked the start of a season of “comings and goings” to and from the island, while approaching the start of the election campaign in which must be measured with the Governor Henrique Capriles. “scheduled on Saturday we have to go back (to Cuba) and remain four days”, said. Opposition insists that,...

ZURICH (Reuters) – Roche Holding improved its offer by Illumina for $ 6.7 billion after talking with the shareholders of the firm of gene sequences, in an attempt to get the backing of a reluctant directory to negotiate its sale. The Swiss drugs manufacturer said Thursday that is now offering 51 dollars per share, a rise of 15 percent regard its initial supply of 44,50 dollars. Roche needs to reap the backing of investors before the general Assembly of Illumina next month. “This is a fair offer and I believe that it is beginning to offer to the shareholders of Illumina portion of the value of the Corporation,” said analyst Vontobel, Andrew Weiss. “is also an indication that some people is supporting Roche.” “That may be enough to carry the Illumina management to the table and discuss the offer”, he added. The original offer from Roche – made in January – was discarded by Illumina for being too low and the firm adopted the strategy called the poison pill, a movement with its current shareholders to rein in a hostile buyer. Franz Humer, Chairman of Roche, said in a letter to the Chief Executive Jay Flatley Illumina that the company had decided to increase the offer following “productive discussions” with shareholders and after observing the reactions of the market after the original offer. “If they continue to refuse to...

(Reuters) – the total number of us who are diagnosed with it, or die of cancer is declining, but certain types of obesity-related cancer and inactivity are on the rise, according to the annual report of the situation of cancer in United States. United States cancer rates fell in a 0.6 by % per year between 2004 and 2008, according to the report, based on data from the National Institute of cancer, Control centres and Disease and other sources. For men, the incidence of prostate cancer is reduced by an average of 2.1 per cent per year, while the lung cancer rates fell by 2 percent. In women, lung cancer rates declined in a 1.2 per cent a year, while the incidence of cancer breast, which is associated with obesity, it remained equal. “the incidence of breast cancer was reduced when the “” hormones retreated, but it has now stabilized”, said the Dr. Powell Brown, President of the cancer prevention in the Department of medical in MD Cancer Center Oncology Anderson at the University of Texas in Houston. Brown referred to the discovery of several years of that the hormone replacement therapy for women menopausal increased the risk of disease and breast cancer heart. El Dr. Brown also explained that the trends of the lung cancer in women have followed those of men for about 10 years, reflecting the...

MADRID (Reuters) – the administration of food and medicines of United States ( FDA) requested three months more to review the application for approval of the drug bromide of aclidinio by Almirall and Forest, said Thursday the lab Spanish. “the response of the FDA is expected in July of 2012,” said Almirall said in a statement. In February, an Advisory Committee supported the efficacy of the drug, indicated to treat lung disease chronic (COPD) obstructive, and its experts said that it contributes to help patients breathe better. However, requested that companies conduct surveys to check if there are safety hazards because some patients died from heart problems during the trials. Almirall has also requested approval for the drug in Europe, where he also expects a response this year. (Report of Rodrigo de Miguel); (Edited by Robert Hetz and Ana Laura...